Production (Stage)
Rapid Dose Therapeutics Corp.
RDTCF
$0.1393
-$0.0407-22.61%
OTC PK
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 225.80% | 112.90% | 42.15% | 64.96% | -10.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 225.80% | 112.90% | 42.15% | 64.96% | -10.99% |
| Cost of Revenue | 267.13% | 119.87% | 67.32% | 14.98% | -56.80% |
| Gross Profit | 191.15% | 107.28% | 30.87% | 117.30% | 704.12% |
| SG&A Expenses | 94.68% | 76.67% | 89.25% | 150.79% | -8.12% |
| Depreciation & Amortization | -72.97% | -68.72% | -65.11% | -43.80% | -26.77% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.82% | 46.47% | 62.65% | 85.07% | -1.57% |
| Operating Income | -8.89% | -26.93% | -78.10% | -95.02% | -0.20% |
| Income Before Tax | 23.13% | -38.03% | -46.48% | -120.75% | -58.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 23.13% | -38.03% | -46.48% | -120.75% | -58.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.13% | -38.03% | -46.48% | -120.75% | -58.22% |
| EBIT | -8.89% | -26.93% | -78.10% | -95.02% | -0.20% |
| EBITDA | -16.95% | -49.68% | -139.25% | -161.61% | -11.11% |
| EPS Basic | 33.09% | -14.29% | -22.64% | -90.00% | -49.46% |
| Normalized Basic EPS | 7.94% | -16.28% | -24.24% | -88.00% | -8.62% |
| EPS Diluted | 33.09% | -14.29% | -22.64% | -90.00% | -49.46% |
| Normalized Diluted EPS | 7.94% | -16.28% | -24.24% | -88.00% | -8.62% |
| Average Basic Shares Outstanding | 14.55% | 20.14% | 18.87% | 17.74% | 5.98% |
| Average Diluted Shares Outstanding | 14.55% | 20.14% | 18.87% | 17.74% | 5.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |